AMLX Historical PE Ratio Notes

— Amylyx Pharmaceuticals (NASDAQ: AMLX) is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, most notably amyotrophic lateral sclerosis (ALS). Its flagship product, RELYVRIO (also known as AMX0035), was approved by the FDA in late 2022 for ALS, making Amylyx a revenue-generating commercial-stage company. When examining AMLX historical PE ratio charts & tables, it is important to understand that prior to RELYVRIO's approval & launch, Amylyx typically reported net losses, which means its price-to-earnings (PE) ratio was either undefined or not meaningful for traditional analysis. As revenue began to flow in from RELYVRIO sales, earnings trajectories shifted, allowing the market to start assigning a PE ratio to the company. PE ratios for emerging biopharma companies like Amylyx can fluctuate dramatically based on regulatory progress, launch performance, and future growth expectations. Keep in mind that periods of negative earnings will show a “N/A” or extremely high/negative PE, while periods following product approval will usually provide the first valid, forward-looking valuations. Thus, changes in AMLX's historical PE ratio mainly reflect the transition from a pre-commercial biotech to a commercial-stage pharma, directly influenced by its clinical & regulatory milestones.

On this page we presented the AMLX Historical PE Ratio information for Amylyx Pharma' stock. The average AMLX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 113.4. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average AMLX historical PE based on this TTM earnings result method is 17.1. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this AMLX historical PE result, against the recent PE: when this page was posted on 8/21/2026, the most recent closing price for AMLX had been 38.66, and the most recent quarterly earnings result, annualized, was 0.28. Meanwhile, the most recent TTM earnings summed to 0.25. From these numbers, we calculate the recent AMLX PE on 8/21/2026 based on annualized quarterly EPS was 138.1. Based on AMLX's history, that recent PE is elevated relative to the historical average, with the recent PE 21.8% higher than the historical average PE across our data set for Amylyx Pharma. Looking at the recent AMLX PE on 8/21/2026 based on TTM EPS, we calculate the ratio at 154.6. Based on AMLX's history, that recent PE is elevated relative to the historical average, with the recent PE 804.1% higher than the historical average PE across our Amylyx Pharma data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on AMLX or any other given stock, valuation analysis for AMLX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Amylyx Pharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for AMLX. Thanks for visiting, and the next time you need to research AMLX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.